IOM suggests FDA monitor drugs' safety regularly

The Institute of Medicine recommended the FDA oversee drug safety regularly to address additional risks. The FDA indicated reservation about the cost of "life cycle" drug monitoring because this could compromise other regulatory tasks.

View Full Article in:

U.S. needs better way to track drug safety - study - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC